The overarching goal of the Experimental Therapeutics Program (ETP) is to build a world-class academic center dedicated to bridging basic and translational science for the design of Innovative and Impactful cancer therapies. This program, originally named the Molecular Therapeutics program, was established in December 2004 and brings together an interdisciplinary group of 41 investigators from 15 different departments. Since the last funding cycle the research base of the Experimental Therapeutics Program increased 104% from $7,878,482 to $16,042,852 total annual direct support with a total annual direct research support, of which $3,683,482 is from the NCI. Over the last grant period, there were a total of 539 publications of the Experimental Therapeutics Program members, of which 9.3% are intra-programmatic and 21.1% are inter-programmatic. Led by Shaomeng Wang, Ph.D. and Judith Sebolt-Leopold, Ph,D., the ETP has a strong focus on the rational design and development of small-molecule targeted therapies and serves as a critical link between the basic science and clinical programs. The ETP has four major research themes: I) Identification of novel therapeutic agents and approaches that target key signaling pathways dysregulated in human cancer, II) Improvement of drug delivery systems to address tumor inaccessibility using nanotechnology platforms, III) Execution of lead optimization and preclinical biomarker studies to guide development candidate selection and clinical trial design, IV) Translation of these new cancer medicines and approaches into the clinic.

Public Health Relevance

All of the research in the Experimental Therapeutics Program (ETP) has direct cancer relevance, Research objectives of Program investigators are directed toward the Identification of novel therapeutic agents and approaches for the treatment of cancer and translating these new cancer medicines in the clinic. To maximize ultimate clinical Impact, the ETP serves as a critical link between the basic science and clinical programs to enable the development of personalized therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046592-24
Application #
8300274
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-06-01
Project End
2017-05-31
Budget Start
2012-09-21
Budget End
2013-05-31
Support Year
24
Fiscal Year
2012
Total Cost
$540,700
Indirect Cost
$192,763
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Feng, Mary; Suresh, Krithika; Schipper, Matthew J et al. (2018) Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 4:40-47
Xiong, Yi; Torsoni, Adriana Souza; Wu, Feihua et al. (2018) Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases. Elife 7:
El Kadi, Najwa; Wang, Luo; Davis, April et al. (2018) The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer. Cancer Res 78:6728-6735
Namkoong, Sim; Ho, Allison; Woo, Yu Mi et al. (2018) Systematic Characterization of Stress-Induced RNA Granulation. Mol Cell 70:175-187.e8
Thomas, Tina T; Chukkapalli, Sahiti; Van Noord, Raelene A et al. (2018) Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts. J Vis Exp :
Eisenberg, Marisa C; Campredon, Lora P; Brouwer, Andrew F et al. (2018) Dynamics and Determinants of HPV Infection: The Michigan HPV and Oropharyngeal Cancer (M-HOC) Study. BMJ Open 8:e021618
Boonstra, Philip S; Barbaro, Ryan P (2018) Incorporating historical models with adaptive Bayesian updates. Biostatistics :
Johnson, Allison M; Roach, James P; Hu, Anna et al. (2018) Connexin 43 gap junctions contribute to brain endothelial barrier hyperpermeability in familial cerebral cavernous malformations type III by modulating tight junction structure. FASEB J 32:2615-2629
Feinberg, Tamar Y; Zheng, Huarui; Liu, Rui et al. (2018) Divergent Matrix-Remodeling Strategies Distinguish Developmental from Neoplastic Mammary Epithelial Cell Invasion Programs. Dev Cell 47:145-160.e6
Hrycaj, Steven M; Marty-Santos, Leilani; Cebrian, Cristina et al. (2018) Hox5 genes direct elastin network formation during alveologenesis by regulating myofibroblast adhesion. Proc Natl Acad Sci U S A 115:E10605-E10614

Showing the most recent 10 out of 1493 publications